News By Tag
News By Location
Nemucore Medical Innovations Presents at 4th Annual CCNE National Cancer Institute Site Visit
By: Nemucore Medical Innovations, Inc.
CCNEs are multi-institutional hubs run by the OCNR, whose focus is on using nanotechnology for advances in cancer research. In 2010 NMI was awarded five years of funding as the translational core of the CCNE’s Center for Translational Cancer Nanomedicine (Center). Dr. Timothy Coleman, CEO & President of NMI, presented on NMI’s translational efforts of scaling up the manufacturing processes of nanomedicines. The presentation included a demonstration of NMI’s Pharma-Designs software package, which aims to eliminate a major communication bottleneck slowing the translation of cancer nanomedicines to the clinic.
Other Center presenters included principal investigators Dr. Vladimir Torchilin, Dr. Mansoor Amiji, Dr. Craig Ferris, Dr. Sri Sridhar, and Dr. Nahum Goldberg.
NMI is dedicated to designing, investigating, developing, and commercializing life-saving novel nanomedicines for the treatment of ovarian cancer and other unmet medical needs. Ultimately, NMI’s products will be part of the personalized medicine revolution occurring in cancer therapies. Our unique focus on reducing the complex nature of nanomedicine manufacturing is expected to enhance the speed by which we translate novel therapeutics to the clinic. As a participant in the National Cancer Institute's Centers for Cancer Nanotechnology Excellence, we are building a state of the art biomanufacturing facility as a national resource for nanomedicine and emerging biopharmaceutical community. NMI was founded in 2008 and is based in Worcester, Massachusetts. For more information, please visit http://www.nemucore.com.
About the Centers for Cancer Nanotechnology Excellence
The National Cancer Institute’s (NCI) Alliance for Nanotechnology in Cancer (http://nano.cancer.gov) program funds nine Centers for Cancer Nanotechnology Excellence (CCNE) across the United States. CCNEs bring together physical scientists, engineers and technologists who work at the nanoscale with cancer biologists and oncologists who specialize in the diagnosis, prevention and treatment of cancer. These multi-disciplinary centers conduct pre-clinical to clinical research to further the application of nanotechnology in clinical oncology.
Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.